UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Journal of clinical oncology, 2019-03, Vol.37 (9), p.741-750

2019

Volltextzugriff (PDF)

Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy

Seminars in cancer biology, 2022-05, Vol.80, p.1-17

2022

Volltextzugriff (PDF)

Management of adverse events associated with idelalisib treatment: expert panel opinion

Leukemia & lymphoma, 2015-10, Vol.56 (10), p.2779-2786

2015

Volltextzugriff (PDF)

Targeting the Phosphatidylinositol 3‐Kinase Signaling Pathway in Breast Cancer

The oncologist (Dayton, Ohio), 2011-01, Vol.16 (4), p.404-414

2011

Volltextzugriff (PDF)

Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression

Cancer discovery, 2016-08, Vol.6 (8), p.870-885

2016

Volltextzugriff (PDF)

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives

Journal of clinical oncology, 2014-09, Vol.32 (25), p.2794-2803

2014

Volltextzugriff (PDF)

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients

Oncotarget, 2010-06, Vol.1 (2), p.89-103

2010

Volltextzugriff (PDF)

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

Molecular cancer therapeutics, 2012-02, Vol.11 (2), p.317-328

2012

Volltextzugriff (PDF)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

Oncotarget, 2016-05, Vol.7 (22), p.33440-33450

2016

Volltextzugriff (PDF)

At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy

Nature reviews. Clinical oncology, 2022-07, Vol.19 (7), p.471-485

2022

Volltextzugriff (PDF)

Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2

JNCI : Journal of the National Cancer Institute, 2017-01, Vol.109 (1), p.djw189

2017

Volltextzugriff (PDF)

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation

Journal of clinical oncology, 2015-08, Vol.33 (22), p.e93-e96

2015

Volltextzugriff (PDF)

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes

Breast cancer research : BCR, 2019-08, Vol.21 (1), p.90-90, Article 90

2019

Volltextzugriff (PDF)

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability

Cancer discovery, 2011-07, Vol.1 (2), p.170-185

2011

Volltextzugriff (PDF)

Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer

Cancer discovery, 2016-03, Vol.6 (3), p.270-285

2016

Volltextzugriff (PDF)

The present and future of PI3K inhibitors for cancer therapy

Nature cancer, 2021-06, Vol.2 (6), p.587-597

2021

Volltextzugriff (PDF)

Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer

Endocrine-related cancer, 2013-06, Vol.20 (3), p.R83-R99

2013

Volltextzugriff (PDF)

TRIP4 promotes tumor growth and metastasis and regulates radiosensitivity of cervical cancer by activating MAPK, PI3K/AKT, and hTERT signaling

Cancer letters, 2019-06, Vol.452, p.1-13

2019

Volltextzugriff (PDF)

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

Cancer cell, 2011-05, Vol.19 (5), p.575-586

2011

Volltextzugriff (PDF)

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma

Cancer biology & therapy, 2015-01, Vol.16 (4), p.602-609

2015

Volltextzugriff (PDF)

Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer

Gynecologic oncology, 2014-05, Vol.133 (2), p.346-352

2014

Volltextzugriff (PDF)

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2012-08, Vol.7 (8), p.1315-1326

Papadimitrakopoulou, Vassiliki

2012

Volltextzugriff (PDF)

Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes

Gynecologic oncology, 2016-09, Vol.142 (3), p.548-556

2016

Volltextzugriff (PDF)

Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition

Breast cancer research : BCR, 2016-04, Vol.18 (1), p.41-41, Article 41

2016

Volltextzugriff (PDF)

The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism

European journal of cancer (1990), 2021-04, Vol.147, p.63-73

2021

Volltextzugriff (PDF)

1 – 25 von 5.826

Suche als RSS-Feed

Aktive Filter

ThemaApoptosis

ThemaBiological And Medical Sciences

ThemaKinases

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.399)
Mit Volltextzugriff
(4.432)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(4.771)
Life Sciences & Biomedicine
(4.723)
Humans
(3.735)
Animals
(1.733)
Female
(1.428)
Cell Line, Tumor
(1.143)
Signal Transduction
(1.133)
Phosphatidylinositol 3-Kinases - Metabolism
(1.059)
Cancer
(930)
Mice
(864)
Proto-Oncogene Proteins C-Akt - Metabolism
(863)
Medicine
(774)
Cell Biology
(740)
Male
(722)
Breast Cancer
(663)
Medicine & Public Health
(639)
Cancer Research
(636)
Tumors
(578)
Signal Transduction - Drug Effects
(548)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy

Management of adverse events associated with idelalisib treatment: expert panel opinion

Targeting the Phosphatidylinositol 3‐Kinase Signaling Pathway in Breast Cancer

Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy

Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability

Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer

The present and future of PI3K inhibitors for cancer therapy

Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer

TRIP4 promotes tumor growth and metastasis and regulates radiosensitivity of cervical cancer by activating MAPK, PI3K/AKT, and hTERT signaling

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma

Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer

Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes

Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition

The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism

Aktive Filter

Suchergebnisse filtern